Research study Program year 2025 Source: CMS Open Payments

A Phase 3, Multicenter, Open Label, Long Term Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease

ClinicalTrials.gov NCT04232553

Research payments

$4,550,377

423 payments

Through program year 2025, $4,550,377 in research payments was reported against A Phase 3, Multicenter, Open Label, Long Term Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease, across 423 payments, paid by Eli Lilly and Company.

Paid by: Eli Lilly and Company
ClinicalTrials.gov: NCT04232553

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,072,731	96
2024	Research	$1,274,821	104
2022	Research	$1,118,136	99
2021	Research	$851,892	78
2020	Research	$232,797	46

Breakdown

Who paid Research payments · program years 2020–2025

Eli Lilly and Company $4,550,377 423 payments

Who received the money Research payments · program years 2020–2025

Care Access Research LLC Organisation paid for research $397,747 28 payments
Sfct A Member Of The Alliance INC Organisation paid for research $281,284 6 payments
Grand Teton Research Group Pllc Organisation paid for research $226,335 8 payments
Delta Research Partners LLC Organisation paid for research $225,037 11 payments
Washington Gastroenterology Pllc Organisation paid for research $200,701 15 payments
Indiana University Organisation paid for research $186,572 10 payments
Clinical Research Of West Florida INC Organisation paid for research $182,096 10 payments
Benaroya Research Institute at Virginia Mason Organisation paid for research $160,401 6 payments
Ihs Health LLC Organisation paid for research $151,670 6 payments
Uh Cleveland Medical Center Teaching hospital · OH $141,003 10 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.